Mafalda Bourbon

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1841584/mafalda-bourbon-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	1,638 citations	24 h-index	39 g-index
74 ext. papers	2,124 ext. citations	4.6 avg, IF	4.41 L-index

#	Paper	IF	Citations
69	Performance comparison of different classification algorithms applied to the diagnosis of familial hypercholesterolemia in paediatric subjects.. *Scientific Reports*, **2022**, 12, 1164	4.9	0
68	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
67	Polygenic contribution for familial hypercholesterolemia (FH). *Current Opinion in Lipidology*, **2021**, 32, 392-395	4.4	0
66	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification.. *Genetics in Medicine*, **2021**,	8.1	6
65	Pharmacogenomics of statins and familial hypercholesterolemia. *Current Opinion in Lipidology*, **2021** , 32, 96-102	4.4	1
64	Machine learning modelling of blood lipid biomarkers in familial hypercholesterolaemia versus polygenic/environmental dyslipidaemia. *Scientific Reports*, **2021**, 11, 3801	4.9	1
63	Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. *Atherosclerosis*, **2021**, 319, 108-117	3.1	5
62	LDLR variants functional characterization: Contribution to variant classification. *Atherosclerosis*, **2021**, 329, 14-21	3.1	2
61	Applicability of Martin-Hopkins formula and comparison with Friedewald formula for estimated low-density lipoprotein cholesterol in e_COR study population. *Revista Portuguesa De Cardiologia (English Edition)*, **2021**, 40, 715-724	0	1
60	Characterization of Two Variants at Met 1 of the Human Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes. *Biomedicines*, **2021**, 9,	4.8	1
59	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
58	Familial hypercholesterolemia **2021**, 323-348		0
57	Brown Algae Potential as a Functional Food against Hypercholesterolemia: Review. *Foods*, **2021**, 10,	4.9	7
56	Recommendations for genetic testing in cardiology: Review of major international guidelines. *Revista Portuguesa De Cardiologia*, **2020**, 39, 597-610	1	0
55	Recommendations for genetic testing in cardiology: Review of major international guidelines. *Revista Portuguesa De Cardiologia (English Edition)*, **2020**, 39, 597-610	0	
54	What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?. *Obesity Surgery*, **2020**, 30, 560-568	3.7	2
53	The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. *Clinical Genetics*, **2020**, 97, 457-466	4	15

52	Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. *Atherosclerosis*, **2020**, 292, 178-187	3.1	17
51	Prevalence and risk factors of fatty liver in Portuguese adults. *European Journal of Clinical Investigation*, **2020**, 50, e13235	4.6	4
50	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2508-2515	9.4	9
49	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 2248-2260	9.4	33
48	Hypercysteinemia, A Potential Risk Factor for Central Obesity and Related Disorders in Azores, Portugal. *Journal of Nutrition and Metabolism*, **2019**, 2019, 1826780	2.7	4
47	Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. *Genetics in Medicine*, **2018**, 20, 591-598	8.1	51
46	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *Journal of the American College of Cardiology*, **2018**, 72, 662-680	15.1	215
45	No Evidence for Lower Levels of Serum Vitamin D in the Presence of Hepatic Steatosis. A Study on the Portuguese General Population. *International Journal of Medical Sciences*, **2018**, 15, 1778-1786	3.7	3
44	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. *Atherosclerosis*, **2018**, 277, 448-456	3.1	12
43	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
42	Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. *Atherosclerosis*, **2018**, 277, 457-463	3.1	28
41	ClinVar database of global familial hypercholesterolemia-associated DNA variants. *Human Mutation* , **2018**, 39, 1631-1640	4.7	55
40	Preliminary spectrum of genetic variants in familial hypercholesterolemia in Argentina. *Journal of Clinical Lipidology*, **2017**, 11, 524-531	4.9	7
39	Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. *Atherosclerosis*, **2017**, 262, 8-13	3.1	42
38	Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia. *Current Opinion in Lipidology*, **2017**, 28, 120-129	4.4	26
37	Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bol□ar, Venezuela. *Endocrinolog□a Diabetes Y Nutrici□n (English Ed)*, **2017**, 64, 432-439	0.1	
36	Applicability of the low-density lipoprotein cholesterol gene score in a South European population. *Atherosclerosis*, **2017**, 263, e99-e100	3.1	2
35	Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bol□ar, Venezuela. *Endocrinologia, Diabetes Y Nutrici□n*, **2017**, 64, 432-439	1.3	1

34	Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. *Journal of Clinical Lipidology*, **2017**, 11, 160-166	4.9	14
33	Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia?. *Journal of Clinical Lipidology*, **2017**, 11, 477-484.e2	4.9	33
32	Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. *Genetics in Medicine*, **2016**, 18, 316-24	8.1	27
31	Immune cell changes in response to a swimming training session during a 24-h recovery period. *Applied Physiology, Nutrition and Metabolism*, **2016**, 41, 476-83	3	7
30	Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. *European Journal of Gastroenterology and Hepatology*, **2016**, 28, 640-4	2.2	14
29	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atherosclerosis Supplements*, **2016**, 22, 1-32	1.7	60
28	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. *Genetics in Medicine*, **2015**, 17, 980-8	8.1	27
27	Pharmacogenetic profile of a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal. *Public Health Genomics*, **2015**, 18, 139-50	1.9	4
26	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. *Circulation: Cardiovascular Genetics*, **2015**, 8, 823-31		76
25	Familial hypercholesterolaemia: A global call to arms. *Atherosclerosis*, **2015**, 243, 257-9	3.1	123
24	Structural analysis of APOB variants, p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del), causing Familial Hypercholesterolaemia provides novel insights into variant pathogenicity. *Scientific Reports* , **2015**, 5, 18184	4.9	28
23	«Papa Bem»: investir na literacia em sa□e para a preven□ da obesidade infantil. *Revista Portuguesa De Saude Publica*, **2015**, 33, 12-23		2
22	Characterization of the first PCSK9 gain of function homozygote. *Journal of the American College of Cardiology*, **2015**, 66, 2152-2154	15.1	27
21	Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal. *Diabetology and Metabolic Syndrome*, **2014**, 6, 23	5.6	12
20	How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. *Liver International*, **2014**, 34, e111-7	7.9	52
19	Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. *Human Molecular Genetics*, **2014**, 23, 1817-28	5.6	58
18	Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia. *Journal of Lipid Research*, **2014**, 55, 947-55	6.3	16
17	Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment. *PLoS ONE*, **2014**, 9, e112677	3.7	29

16	Cardiovascular risk profile of high school students: a cross-sectional study. *Revista Portuguesa De Cardiologia*, **2014**, 33, 525-34	1	5
15	Familial hypercholesterolemia: Molecular characterization of possible cases from the Azores Islands (Portugal). *Meta Gene*, **2014**, 2, 638-45	0.7	2
14	Hypercholesterolemia--a disease with expression from childhood. *Revista Portuguesa De Cardiologia* , **2013**, 32, 379-86	1	5
13	Sortilin and the risk of cardiovascular disease. *Revista Portuguesa De Cardiologia*, **2013**, 32, 793-9	1	4
12	Hypercholesterolemia A disease with expression since childhood. *Revista Portuguesa De Cardiologia (English Edition)*, **2013**, 32, 379-386	0	3
11	In´vitro functional characterization of missense mutations in the LDLR gene. *Atherosclerosis*, **2012**, 225, 128-34	3.1	18
10	Update of the Portuguese Familial Hypercholesterolaemia Study. *Atherosclerosis*, **2010**, 212, 553-8	3.1	42
9	Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. *Journal of Medical Genetics*, **2009**, 46, 352-7	5.8	35
8	Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations. *Clinical Genetics*, **2008**, 74, 267-73	4	21
7	Familial hypercholesterolaemia in Portugal. *Atherosclerosis*, **2008**, 196, 633-42	3.1	71
6	A rare polymorphism in the low density lipoprotein (LDL) gene that affects mRNA splicing. *Atherosclerosis*, **2007**, 195, e17-20	3.1	20
5	Portuguese Familial Hypercholesterolemia Study: presentation of the study and preliminary results. *Revista Portuguesa De Cardiologia*, **2006**, 25, 999-1013	1	10
4	Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 832-7	9.4	54
3	Inheritance of two different alleles of the low-density lipoprotein (LDL)-receptor gene carrying the recurrent Pro664Leu mutation in a patient with homozygous familial hypercholesterolaemia. *Clinical Genetics*, **1999**, 56, 225-31	4	5
2	Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. *Journal of Clinical Investigation*, **1999**, 104, 619-28	15.9	67
1	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification		1